<?xml version="1.0" encoding="UTF-8" standalone="yes"?><dealRecordsOutput><serviceExecutionTime>243</serviceExecutionTime><Deal id="157766"><Title>Xuanzhu Pharma and RaQualia to develop pre-clinical compounds for ion channel target against pain          </Title><CompanyPrincipal id="1040956">RaQualia Pharma Inc</CompanyPrincipal><CompanyPartner id="1099478">Xuanzhu Pharma Co Ltd</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="Payment Unspecified" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><TerritoriesExcluded><Territory id="CN">China</Territory><Territory id="HK">Hong Kong</Territory><Territory id="MO">Macau</Territory><Territory id="TW">Taiwan</Territory></TerritoriesExcluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>2069485</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1723182</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1723182</Reference><Type>Upfront Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>2069485</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1723182</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1723182</Reference><Type>Upfront Payment</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="20">Pain</Indication></Indications><ActionsPrimary><Action id="1095">Ion channel modulator</Action><Action id="24308">SCN9A sodium channel subunit inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><DateStart>2015-12-22T00:00:00Z</DateStart><DateEnd>2018-08-31T00:00:00Z</DateEnd><DateEventMostRecent>2018-08-31T00:00:00Z</DateEventMostRecent><Drugs><Drug id="100342"><DrugNameDisplay>RQ-00488738</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In December 2015, &lt;ulink linkType="Company" linkID="1099478"&gt;XuanZhu Pharma&lt;/ulink&gt; signed an exclusive worldwide  three year research collaboration  with &lt;ulink linkType="Company" linkID="1040956"&gt;RaQualia Pharma&lt;/ulink&gt; to develop and commercialize   &lt;ulink linkType="Drug" linkID="100342"&gt;compounds for a specific ion channel target&lt;/ulink&gt; against pain excluding China, Taiwan, Hong Kong and Macao [&lt;ulink linkType="Reference" linkID="1723182"&gt;1723182&lt;/ulink&gt;].  In August 2018,  RaQualia's board of directors agreed to dissolve the collaboration agreement and signed a memorandum of understanding (MOU) with XuanZhu following early positive results achieved from the research collaboration [&lt;ulink linkType="Reference" linkID="2069485"&gt;2069485&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2069789"&gt;2069789&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2018-08-31T00:00:00Z</Date><Drugs><DrugLink id="100342" nameDisplay="RQ-00488738"/></Drugs><Stage id="DR">Discovery</Stage><Summary>&lt;para&gt;- In August 2018,  RaQualia's board of directors agreed to dissolve the collaboration agreement and signed a memorandum of understanding (MOU) with XuanZhu following early positive results achieved from the research collaboration.&lt;/para&gt;&lt;para&gt;- The parties agreed to engage in independent R&amp;amp;D based on their individual research results.&lt;/para&gt;&lt;para&gt;- The parties would pay each other royalties if it is possible to secure earnings based on each other's research results.&lt;/para&gt;&lt;para&gt;- The parties would jointly announce research results belonging to RaQualia at the 17th World Congress on Pain in September 2018 [&lt;ulink linkType="Reference" linkID="2069485"&gt;2069485&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2069789"&gt;2069789&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event><Event><Date>2015-12-22T00:00:00Z</Date><Drugs><DrugLink id="100342" nameDisplay="RQ-00488738"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1723182">1723182</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPrincipal><Stage id="PC">Preclinical</Stage><Summary>&lt;para&gt;- In December 2015, &lt;ulink linkType="Company" linkID="1099478"&gt;XuanZhu Pharma&lt;/ulink&gt; signed an worldwide exclusive  three year research collaboration  with &lt;ulink linkType="Company" linkID="1040956"&gt;RaQualia Pharma&lt;/ulink&gt; to develop and commercialize   &lt;ulink linkType="Drug" linkID="100342"&gt;compounds for a specific ion channel target&lt;/ulink&gt; against pain excluding China, Taiwan, Hong Kong and Macao.&lt;/para&gt;&lt;para&gt;- RaQualia would provide its technical knowledge on ion channel and pain as well as human resources, and would be granted with worldwide exclusive rights excluding China, Taiwan, Hong Kong and Macao to commercialize the drug candidate.&lt;/para&gt;&lt;para&gt;- XuanZhu would provide its technology, human resources and funding to the joint research, and would initiate pre-clinical trials for the candidate compound to file an IND in China and would be granted exclusive rights to manufacture and market the product in China, Taiwan, Hong Kong and Macao.&lt;/para&gt;&lt;para&gt;- XuanZhu would conduct non-clinical and clinical studies to submit a New Drug Application (NDA).&lt;/para&gt;&lt;para&gt;- Both the parties would distribute to the other party a part of their revenues generated from the commercialization of the product in each area.&lt;/para&gt;&lt;para&gt;-  RaQualia would receive undisclosed upfront payment [&lt;ulink linkType="Reference" linkID="1723182"&gt;1723182&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="1099478" type="Company"><TargetEntity id="4297910172" type="organizationId">Shandong Xuanzhu Pharmaceutical Technology Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1040956" type="Company"><TargetEntity id="4298032666" type="organizationId">RaQualia Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="1095" type="Action"><TargetEntity id="353" type="Mechanism">DRUGS ACTING ON ION CHANNELS</TargetEntity><TargetEntity id="2510" type="Mechanism">DRUGS ACTING ON TRANSMITTER-GATED CHANNELS</TargetEntity></SourceEntity><SourceEntity id="24308" type="Action"><TargetEntity id="2733" type="Mechanism">Sodium Channel Protein Type 9 Subunit alpha (Nav1.7) Channel Blockers</TargetEntity></SourceEntity></CrossReferences></Deal></dealRecordsOutput>